^
    Back
    Association details:
    Biomarker:KAT6A-NRG1 fusion
    Cancer:Renal Cell Carcinoma
    Drug:Opdivo (nivolumab) (PD1 inhibitor) +
    Yervoy (ipilimumab) (CTLA4 inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C4 – Case Studies
    Source:
    Front Oncol
    Title:

    Case Report: Disease progression of renal cell carcinoma containing a novel putative pathogenic KAT6A::NRG1 fusion on Ipilimumab- Nivolumab immunotherapy. A case study and review of the literature

    Published date:
    02/02/2023
    Excerpt:
    ...we present a case of a 49 year old man with an aggressive renal cell carcinoma bearing a novel pathogenic KAT6A::NRG1 fusion….A repeat CT Abdomen pelvis taken after 4 months of treatment with Ipilimumab-Nivolumab showed enlargement of the para-aortic lymph node to 3.6cm, increasing to 4.3cm on MRI at 6 months. This 72% increase in size from 2.5cm to 4.3 cm indicates disease progression despite on combination IPI-NIVO therapy.
    DOI:
    https://doi.org/10.3389/fonc.2023.1111706